Detecting Early Recurrence With Circulating Tumor DNA in Stage I-III Biliary Tract Cancer After Curative Resection
JCO Precision Oncology · 2025-01 · (9)
DOI: 10.1200/po-24-00443 ↗Kurz gefasst
Evaluationsstudie in der Zeitschrift JCO Precision Oncology, 2025-01. Verfasst von James Yu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center, Tampa, FL. Hauptthemen laut MEDLINE: Biliary Tract Neoplasms, Circulating Tumor DNA, Neoplasm Recurrence, Local, Neoplasm Staging. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE This study aimed to assess (1) the prognostic value of circulating tumor DNA (ctDNA) and (2) the ability of ctDNA to detect recurrence compared with standard surveillance in curatively resected early-stage biliary tract cancer (BTC). METHODS This retrospective, multicenter cohort study evaluated serial ctDNA testing for surveillance in patients with early-stage BTC after curative resection. We evaluated the relapse-free survival (RFS) by ctDNA positivity. The sensitivity of ctDNA in detecting a confirmed recurrence of BTC, defined as a biopsy-proven or true progression by radiographic tumor dynamics, was evaluated. The lead time was calculated from the first ctDNA detection to the confirmed recurrence. RESULTS A total of 56 patients with curatively resected stage I-III BTC were included in this study, with a median follow-up of 12.8 months from the date of surgery. ctDNA detection during the molecular residual disease window period (median RFS, 6.6 months v not reached; hazard ratio [HR], 26 [95% CI, 2.6 to 265]; P < .0001) and during the surveillance period (median RFS, 19.3 months v not reached; HR, 20 [95% CI, 2.6 to 153]; P < .0001) were associated with poorer RFS. Sixteen patients had confirmed recurrence. ctDNA identified recurrence in 93.8.% (15/16) of the recurred patients with an average lead time of 3.7 months. Carbohydrate antigen 19-9 levels did not show any significant correlation with RFS (HR, 1.17 [95% Cl, 0.24 to 5.71]; P = .844) in contrast to ctDNA. CONCLUSION The findings from our real-world cohort study revealed the (1) promising value of ctDNA as a prognostic biomarker for relapse in curatively resected BTC and (2) potential early detectability of recurrence by ctDNA compared with standard surveillance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center, Tampa, FL.
- Department of Gastrointestinal Oncology, MedStar Georgetown University Hospital, Washington, DC.
- Natera, Inc, Austin, TX.
ORCID-Profile: James Yu, Aiwu Ruth He, Mahmoud Ouf, Rutika Mehta, Daniel A Anaya, Catherine Bridges, Vasily N Aushev, Adham Jurdi, Minetta C Liu, Richard D Kim
Förderung
- NCI NIH HHS
Zitieren
APA
Yu, J., He, A. R., Ouf, M., Mehta, R., Anaya, D. A., Denbo, J., Bridges, C., Tin, A., Aushev, V. N., Palsuledesai, C. C., Sharma, S., Jurdi, A., Liu, M. C., & Kim, R. D. (2025). Detecting Early Recurrence With Circulating Tumor DNA in Stage I-III Biliary Tract Cancer After Curative Resection. JCO Precision Oncology. https://doi.org/10.1200/po-24-00443
Vancouver
Yu J, He AR, Ouf M, Mehta R, Anaya DA, Denbo J, et al. Detecting Early Recurrence With Circulating Tumor DNA in Stage I-III Biliary Tract Cancer After Curative Resection. JCO Precision Oncology. 2025. doi:10.1200/po-24-00443
BibTeX
@article{Yu2025,
author = {Yu, James and He, Aiwu Ruth and Ouf, Mahmoud and Mehta, Rutika and Anaya, Daniel A and Denbo, Jason and Bridges, Catherine and Tin, Antony and Aushev, Vasily N and Palsuledesai, Charuta C and Sharma, Shruti and Jurdi, Adham and Liu, Minetta C and Kim, Richard D},
title = {Detecting Early Recurrence With Circulating Tumor DNA in Stage I-III Biliary Tract Cancer After Curative Resection},
journal = {JCO Precision Oncology},
year = {2025},
number = {9},
doi = {10.1200/po-24-00443}
}
EUVIMED